Loading
The claim is simple enough to write on one line. Each calendar year takes a year of remaining life expectancy away from you, and rejuvenation research gives some of it back. If the giving back ever exceeds the taking away, and keeps exceeding it, you stop having a projected date of death. This page runs that sum year by year and shows you where it lands.
r(y+1) = r(y) − 1 + g(y)
r is remaining life expectancy, g is the gain delivered in that calendar year. Escape is not “g crossed 1.0 once” — it is g staying at or above 1.0 for good, which is why the model tracks the whole trajectory rather than a single crossing.
Where you are standing when the clock starts, in 2026.
Years you would expect to live from here with no further progress. Defaults to a high-income period life table: 40.5 at age 40.
Before this year the gain is zero. Nothing in the literature fixes this date; it is the second-largest guess on the page.
Years of remaining life expectancy returned per calendar year once therapies arrive. 1.00 is break-even. The historical record is nearer 0.20, and it came from other causes.
Compounding change in the gain each year. Negative if the easy problems are solved first; positive if progress feeds on itself.
2051age 65.021.0 yr leftgain 0.50
Age 107
Projected death in 2093. The gain never holds above break-even for long enough, so remaining life expectancy keeps drifting down and reaches zero.
It is a caricature. One state variable, one difference equation, no biology in it anywhere. Everything except the gain rate is bookkeeping, which means the gain rate is the entire argument. Move it from 0.95 to 1.05 and the conclusion inverts, with nothing else changed.
No such sustained rate has ever been demonstrated in humans. Best-practice life expectancy at birth — whichever country holds the record — rose about 0.25 years per calendar year for roughly 160 years, and nearly all of that came from infants and infections rather than from ageing more slowly. Remaining life expectancy at 65 has improved nearer 0.1 per year, and in several rich countries the improvement stalled after 2010. Nothing in any species has produced a compounding gain above 1.0.
The model also assumes gains arrive for everyone at once, work on the first attempt, cost nothing, and never run into an accident floor. Put the floor back and the ceiling returns: at 50 extrinsic deaths per 100,000 per year, remaining life expectancy cannot exceed about 2,000 years however completely ageing is solved. You can see that term directly in the lifespan explorer.
Most biogerontologists reject near-term escape timelines. The dispute is not about the arithmetic, which is trivially correct. It is about whether any intervention can deliver a compounding annual gain of this size — and about whether talking in these terms makes the field easier or harder to fund seriously.
Each of these makes escape easier to reach than it would be in a model with more biology in it. None of them is hidden anywhere else on the page.
Real life tables are gentler than that at the top end: between 80 and 90, remaining life expectancy falls by around 0.4 years per year of age, not 1.0. The model is therefore pessimistic in late life and roughly right in midlife.
No lag between a result and a clinic, no non-responders, no supply limit, no price. Every year's gain lands on everyone alive that year.
In reality an intervention that removes one cause of death buys far less than one that slows every ageing process at once. Curing all cancer adds roughly three years to life expectancy at birth. This model has no notion of which mechanism the gain came from.
Remaining life expectancy is allowed to grow without limit. It cannot: with extrinsic mortality at 50 deaths per 100,000 per year, the ceiling on remaining life is about 2,000 years no matter how completely ageing is solved.
No variance, no confidence interval, no cohort. The output is a single trajectory, and treating it as a personal forecast would be a category error.
Nothing in the literature fixes the date at which rejuvenation therapies begin returning measurable years. The slider exists because the guess should be visible, not because the model knows.
The hypothetical threshold at which medicine adds remaining life expectancy faster than time subtracts it, making death by aging recede indefinitely.
British biogerontologist who proposed the SENS damage-repair framework for rejuvenation and popularized the idea of longevity escape velocity.
The proposition that aging is the shared upstream driver of most chronic disease, so that slowing it would delay many conditions at once rather than one at a time.
The longest duration a human being has lived or could live, distinct from average life expectancy and disputed as to whether any fixed ceiling exists.
The model underneath this one is the lifespan explorer, which shows where remaining life expectancy comes from in the first place, and why the extrinsic term puts a ceiling on any escape scenario.